PDF(Pubmed)
Abstract：
UNASSIGNED: The Y-box-binding proteins (YBX) act as a multifunctional role in tumor progression, metastasis, drug resistance by regulating the transcription and translation process. Nevertheless, their functions in a pan-cancer setting remain unclear.
UNASSIGNED: This study examined the clinical features expression, prognostic value, mutations, along with methylation patterns of three genes from the YBX family (YBX1, YBX2, and YBX3) in 28 different types of cancer. Data used for analysis were obtained from Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. A novel YBXs score was created using the ssGSEA algorithm for the single sample gene set enrichment analysis. Additionally, we explored the YBXs score\'s association with the tumor microenvironment (TME), response to various treatments, and drug resistance.
UNASSIGNED: Our analysis revealed that YBX family genes contribute to tumor progression and are indicative of prognosis in diverse cancer types. We determined that the YBXs score correlates significantly with numerous malignant pathways in pan-cancer. Moreover, this score is also linked with multiple immune-related characteristics. The YBXs score proved to be an effective predictor for the efficacy of a range of treatments in various cancers, particularly immunotherapy. To summarize, the involvement of YBX family genes is vital in pan-cancer and exhibits a significant association with TME. An elevated YBXs score indicates an immune-activated TME and responsiveness to diverse therapies, highlighting its potential as a biomarker in individuals with tumors. Finally, experimental validations were conducted to explore that YBX2 might be a potential biomarker in liver cancer.
UNASSIGNED: The creation of YBXs score in our study offered new insights into further studies. Besides, YBX2 was found as a potential therapeutic target, significantly contributing to the improvement of HCC diagnosis and treatment strategies.
UNASSIGNED: This study examined the clinical features expression, prognostic value, mutations, along with methylation patterns of three genes from the YBX family (YBX1, YBX2, and YBX3) in 28 different types of cancer. Data used for analysis were obtained from Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. A novel YBXs score was created using the ssGSEA algorithm for the single sample gene set enrichment analysis. Additionally, we explored the YBXs score\'s association with the tumor microenvironment (TME), response to various treatments, and drug resistance.
UNASSIGNED: Our analysis revealed that YBX family genes contribute to tumor progression and are indicative of prognosis in diverse cancer types. We determined that the YBXs score correlates significantly with numerous malignant pathways in pan-cancer. Moreover, this score is also linked with multiple immune-related characteristics. The YBXs score proved to be an effective predictor for the efficacy of a range of treatments in various cancers, particularly immunotherapy. To summarize, the involvement of YBX family genes is vital in pan-cancer and exhibits a significant association with TME. An elevated YBXs score indicates an immune-activated TME and responsiveness to diverse therapies, highlighting its potential as a biomarker in individuals with tumors. Finally, experimental validations were conducted to explore that YBX2 might be a potential biomarker in liver cancer.
UNASSIGNED: The creation of YBXs score in our study offered new insights into further studies. Besides, YBX2 was found as a potential therapeutic target, significantly contributing to the improvement of HCC diagnosis and treatment strategies.
摘要：
■Y盒结合蛋白（YBX）在肿瘤进展中起着多功能作用，转移,通过调节转录和翻译过程产生耐药性。然而，它们在泛癌症环境中的功能仍不清楚。
■这项研究检查了临床特征表达，预后价值，突变,在28种不同类型的癌症中，以及来自YBX家族的三个基因（YBX1，YBX2和YBX3）的甲基化模式。用于分析的数据从癌症基因组图谱(TCGA)和基因型-组织表达(GTEx)数据库获得。使用ssGSEA算法创建新的YBXs评分用于单样品基因集富集分析。此外,我们探索了YBXs评分与肿瘤微环境(TME)的关联，对各种治疗的反应，和抗药性。
■我们的分析显示，YBX家族基因有助于肿瘤进展，并指示不同癌症类型的预后。我们确定YBXs评分与泛癌症中的许多恶性途径显着相关。此外，该评分还与多种免疫相关特征相关.YBXs评分被证明是各种癌症治疗效果的有效预测因子，特别是免疫疗法。总结一下,YBX家族基因的参与在泛癌症中至关重要,并与TME显著相关.升高的YBXs评分表明免疫激活的TME和对不同疗法的反应性，突出了它作为肿瘤个体生物标志物的潜力。最后,进行实验验证以探索YBX2可能是肝癌的潜在生物标志物。
■在我们的研究中创建YBXs评分为进一步的研究提供了新的见解。此外,YBX2被发现是一个潜在的治疗靶点，显着有助于改善HCC的诊断和治疗策略。
■这项研究检查了临床特征表达，预后价值，突变,在28种不同类型的癌症中，以及来自YBX家族的三个基因（YBX1，YBX2和YBX3）的甲基化模式。用于分析的数据从癌症基因组图谱(TCGA)和基因型-组织表达(GTEx)数据库获得。使用ssGSEA算法创建新的YBXs评分用于单样品基因集富集分析。此外,我们探索了YBXs评分与肿瘤微环境(TME)的关联，对各种治疗的反应，和抗药性。
■我们的分析显示，YBX家族基因有助于肿瘤进展，并指示不同癌症类型的预后。我们确定YBXs评分与泛癌症中的许多恶性途径显着相关。此外，该评分还与多种免疫相关特征相关.YBXs评分被证明是各种癌症治疗效果的有效预测因子，特别是免疫疗法。总结一下,YBX家族基因的参与在泛癌症中至关重要,并与TME显著相关.升高的YBXs评分表明免疫激活的TME和对不同疗法的反应性，突出了它作为肿瘤个体生物标志物的潜力。最后,进行实验验证以探索YBX2可能是肝癌的潜在生物标志物。
■在我们的研究中创建YBXs评分为进一步的研究提供了新的见解。此外,YBX2被发现是一个潜在的治疗靶点，显着有助于改善HCC的诊断和治疗策略。
